REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

被引：1
|
作者：
Moog, G. [1 ]
Schober, A. [2 ]
Antoni, C. [3 ]
Bruch, H. R. [4 ]
Herrmann, A. [5 ]
John, C. [6 ]
Steffens, H.
Leuschner, M. [7 ]
Spengler, U. [8 ]
Moeller, B. [6 ,9 ]
Isernhagen, K.
Hueppe, D. [10 ]
Alshuth, U. [11 ]
Mauss, S. [12 ]
机构：
[1] Ctr Gastroenterol, Kassel, Germany
[2] Ctr Gastroenterol, Gottingen, Germany
[3] Univ Med Mannheim, Med Univ Klin 2, Mannheim, Germany
[4] Ctr Gastroenterol, Bonn, Germany
[5] Univ Basel Hosp, Dept Internal Med 2, Jena, Germany
[6] Ctr Gastroenterol, Berlin, Germany
[7] Ctr Hepatol, Offenbach, Germany
[8] Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany
[9] Ctr Liver, Berlin, Germany
[10] Ctr Gastroenterol, Herne, Germany
[11] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany
[12] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60877-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
875
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
    Spengler, U.
    Schober, A.
    John, C.
    Bruch, H. R.
    Heyne, R.
    Antoni, C.
    Herrmann, A.
    Schott, E.
    Steffens, H.
    Hoerster, H. -G.
    Hueppe, D.
    Alshuth, U.
    Mauss, S.
    Buggisch, P.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S374 - S374
  • [2] REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
    Mauss, S.
    Boeker, K. H. W.
    Eisenbach, C.
    Moeller, B.
    Moog, G.
    Lutz, T.
    Naumann, U.
    Christensen, S.
    Jung, M. -C.
    Teuber, G.
    Doss, M. Frank
    Schuchmann, M.
    Schott, E.
    Alshuth, U.
    Hueppe, D.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S357 - S358
  • [3] Real-world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alfa-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
    Buggisch, Peter
    Schober, Andreas
    Bruch, Harald-Robert
    Antoni, Christoph
    Loehr, Hanns-Friedrich F.
    Herrmann, Andreas
    Steffens, Hermann
    Moog, Gero
    Haessner, Joachim
    Hoerster, Hans-Georg
    John, Christine
    Schlueter, Hans-Joachim
    Link, Ralph
    Heyne, Renate
    Spengler, Ulrich
    Alshuth, Ulrich
    Boeker, Klaus H.
    [J]. HEPATOLOGY, 2013, 58 : 1159A - 1159A
  • [4] Efficacy and safety of eRVR patients treated with telaprevir, peginterferon alfa-2A and ribavirin: SVR Data from the German non-interventional PAN Study
    Christensen, Stefan
    Boeker, Klaus H.
    Eisenbach, Christoph
    Schuchmann, Marcus
    Lutz, Thomas
    Heyne, Renate
    Moog, Gero
    Mauss, Stefan
    Jung, Maria-Christina
    Teuber, Gerlinde
    Emke, Franz
    Naumann, Uwe
    Doss, Margareta Frank
    von Lucadou, Armand
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. HEPATOLOGY, 2013, 58 : 1127A - 1127A
  • [5] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    [J]. HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [6] VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS
    Di Bisceglie, A. M.
    Nelson, D. R.
    Gane, E.
    Alves, K.
    Koziel, M. J.
    De Souza, C.
    Kieffer, T. L.
    George, S.
    Kauffman, R. S.
    Jacobson, I. M.
    Sulkowski, M. S.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S540 - S540
  • [7] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY
    Ferenci, P.
    Flisiak, R.
    Caruntu, F. A.
    Lengyel, G.
    Hohmann, M.
    Bakalos, G.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S453 - S454
  • [8] Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin
    Rustgi, VK
    Esposito, S
    Freilich, B
    Lopez-Talavera, JC
    Lentz, E
    Shiffman, ML
    [J]. HEPATOLOGY, 2005, 42 (04) : 692A - 692A
  • [9] Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Mchutchison, J. G.
    Everson, G. T.
    Gordon, S. C.
    Jacobson, I.
    Kauffinan, R.
    McNair, L.
    Muir, A.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S4 - S4
  • [10] BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING
    Hofmann, W. P.
    Mauss, S.
    Baumgarten, A.
    Boeker, K. H. W.
    Link, R.
    Naumann, U.
    Geyer, P. R.
    Schuchmann, M.
    Stoehr, A.
    Loehr, H.
    Schober, A.
    Moog, G.
    Holm, S.
    Heyne, R.
    Eisenbach, C.
    Lutz, T.
    Alshuth, U.
    Hueppe, D.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S466 - S466
12345